Psychoeducation of Parents to Children With FASD
Launched by SORLANDET HOSPITAL HF · Jan 5, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special program can help parents of children with Fetal Alcohol Spectrum Disorders (FASD). FASD can cause challenges in learning and behavior because of brain damage that happens before birth due to alcohol exposure. The goal of this study is to teach parents ways to better understand their children’s needs and help improve their behavior and self-control. By participating in this program, parents will learn useful strategies based on proven methods used around the world.
To be eligible for this trial, children and teenagers aged 2.5 to 18 years who have been exposed to alcohol before birth can participate. The study targets those who have a confirmed history of alcohol exposure during pregnancy, but children who have been adopted and show signs of FASD can also join. However, children with certain conditions, like genetic syndromes or serious vision or hearing problems, will not be included. This program is not yet recruiting participants, but it aims to provide valuable support to families dealing with the effects of FASD.
Gender
ALL
Eligibility criteria
- • All children and adolescents (age 2,5-18 years) referred to the Regional Competence Centre for children with prenatal alcohol exposure in Arendal, Norway will be invited to participate in the current research project.
- Inclusion criteria:
- • Valid information about alcohol exposure in fetal life. Exceptions to this inclusion criterion are children who have been adopted and with dysmorphic features that are consistent with full Fetal Alcohol Syndrome.
- Exclusion Criteria:
- • Children with known genetic syndromes, progressive brain and neuromuscular diseases or major sensory defects (blindness or deafness).
About Sorlandet Hospital Hf
Sørlandet Hospital HF is a leading healthcare institution in Norway dedicated to providing high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, the hospital focuses on innovative healthcare solutions that enhance patient outcomes and contribute to the medical knowledge base. With a commitment to ethical standards and regulatory compliance, Sørlandet Hospital HF collaborates with a diverse range of partners to conduct rigorous studies across various therapeutic areas, ensuring that research findings are both scientifically robust and clinically relevant. The institution's multidisciplinary approach fosters an environment of excellence in patient care and research, positioning it as a key player in the Norwegian healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arendal, , Norway
Patients applied
Trial Officials
Jon S Skranes, Dr Med
Principal Investigator
Sørlandet Hospital HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials